Table 1.
Patient Characteristics
| Characteristic | Carboplatin/Paclitaxel (%)(n = 413) | Carboplatin/Paclitaxel/Sorafenib (%)(n = 410) |
|---|---|---|
| Male sex | 61 | 66 |
| Median age, years | 59 | 61 |
| AJCC stage | ||
| Unresectable stage III | 9 | 9 |
| M1a/M1b | 34 | 34 |
| M1c | 57 | 57 |
| Serum LDH at baseline | ||
| Normal | 61 | 55 |
| Above normal | 39 | 45 |
| ECOG performance status | ||
| 0 | 61 | 61 |
| 1 | 39 | 39 |
| Prior systemic therapy | ||
| None | 58 | 59 |
| Interferon, IL-2, GM-CSF | 38 | 37 |
| Investigational therapy | 4 | 4 |
Abbreviations: AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-2, interleukin-2; LDH, lactate dehydrogenase.